Setmelanotide is a melanocortin-4 receptor (MC4R) agonist designed to treat hyperphagia and obesity. Rhythm is evaluating setmelanotide in a global Phase 3 trial in patients with acquired hypothalamic ...

Unlock the latest advancements in obesity treatment. Expert insights reveal groundbreaking medical breakthroughs and ...

Rhythm Pharmaceuticals (NASDAQ:RYTM – Free Report) had its target price increased by Needham & Company LLC from $64.00 to $66 ...

Charles Schwab Investment Management Inc. grew its holdings in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Free Report) by ...

Zealand Pharma has concluded enrolment for its global, randomised Phase IIb ZUPREME-1 trial, assessing petrelintide.

BRP, identified through peptide prediction, may revolutionize weight loss treatment, offering efficacy without the ...

In November 2024, Zealand Pharma presented detailed results from the Phase 1b 16-week multiple ascending dose (MAD) trial at ...

Basel: Roche has announced that it has entered into an exclusive collaboration and licensing agreement with Zealand Pharma.

I’ve always struggled to increase my sleep quantity, but using expert-approved tricks to improve the quality made the world ...

A 2023 study published in the Obesity journal found that acute sleep deprivation reduces blood concentrations of the hormone leptin ... When bright light hits the receptors on the back of the ...

The identification of BRP, an anti-obesity peptide, showcases the transformative role of AI in drug discovery and its ...